Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Thymoma and Thymic Carcinoma
How do you typically approach adjuvant therapy for a Masaoka stage IVa thymoma post-R0 resection?
Related Questions
For the neoadjuvant treatment for thymoma, when do you favor CAP with prednisone over CAP?
Would you offer a RET inhibitor to a patient with de novo metastatic, RET V706M mutant squamous cell lung cancer?
What are your top takeaways in thoracic cancers from ESMO 2025?
Would you consider starting immunotherapy in a patient with stage IV NSCLC, a high PDL1 level, and active, untreated hepatitis C?
Would you consider bevacizumab for a patient with SCLC who has asymptomatic brain metastasis progression after CNS radiation while on maintenance immunotherapy?
In patients with stage III NSCLC who experience locoregional recurrence after neoadjuvant chemoimmunotherapy, surgery, and maintenance immunotherapy, and are treated with definitive chemoradiation at recurrence—what is the optimal systemic therapy strategy post-chemoradiation?
What is your preferred treatment option after tarlatamab for patients with ES-SCLC?
Would you offer tarlatamab to patients with metastatic EGFR+ NSCLC that transformed into SCLC?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
For patients with stage I NSCLC, do you use RiskReveal, and if so, how do you use it to guide treatment?
